tetano
Editor, Senior Moderator
Drugs
. 2020 Aug 16;1-10.
doi: 10.1007/s40265-020-01377-x. Online ahead of print.
Management of Thrombotic Complications in COVID-19: An Update
Adrija Hajra[SUP] 1 [/SUP], Sheetal Vasundara Mathai[SUP] 2 [/SUP], Somedeb Ball[SUP] 3 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 4 [/SUP], Maedeh Veyseh[SUP] 2 [/SUP], Sandipan Chakraborty[SUP] 5 [/SUP], Carl J Lavie[SUP] 6 [/SUP], Wilbert S Aronow[SUP] 7 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clear, the most widely accepted mechanism is systemic inflammation. A clinically significant effect of the inflammation is coagulopathy. As a result of this effect, patients are found to have a high risk of venous thromboembolism. Studies have reported a high incidence of thrombotic complications in critically ill patients with COVID-19. In this review, we discuss the most updated evidence on the pathophysiology, diagnosis, and treatment of the coagulopathy of COVID-19. Prophylactic anticoagulation is recommended for all in-patients with COVID-19. Those with a higher risk of developing thromboembolic events or who have already developed venous thromboembolism should be treated with therapeutic anticoagulation. We also discuss post-discharge prophylaxis for high-risk patients and some newly proposed treatments for the hypercoagulability that could improve the outcomes of the affected patients.
. 2020 Aug 16;1-10.
doi: 10.1007/s40265-020-01377-x. Online ahead of print.
Management of Thrombotic Complications in COVID-19: An Update
Adrija Hajra[SUP] 1 [/SUP], Sheetal Vasundara Mathai[SUP] 2 [/SUP], Somedeb Ball[SUP] 3 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 4 [/SUP], Maedeh Veyseh[SUP] 2 [/SUP], Sandipan Chakraborty[SUP] 5 [/SUP], Carl J Lavie[SUP] 6 [/SUP], Wilbert S Aronow[SUP] 7 [/SUP]
Affiliations
- PMID: 32803670
- PMCID: PMC7429134
- DOI: 10.1007/s40265-020-01377-x
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clear, the most widely accepted mechanism is systemic inflammation. A clinically significant effect of the inflammation is coagulopathy. As a result of this effect, patients are found to have a high risk of venous thromboembolism. Studies have reported a high incidence of thrombotic complications in critically ill patients with COVID-19. In this review, we discuss the most updated evidence on the pathophysiology, diagnosis, and treatment of the coagulopathy of COVID-19. Prophylactic anticoagulation is recommended for all in-patients with COVID-19. Those with a higher risk of developing thromboembolic events or who have already developed venous thromboembolism should be treated with therapeutic anticoagulation. We also discuss post-discharge prophylaxis for high-risk patients and some newly proposed treatments for the hypercoagulability that could improve the outcomes of the affected patients.